CEP-26401

Teva Branded Pharmaceutical Products R&D, Inc. · Phase 1 active Small molecule

At a glance

Generic name	CEP-26401
Also known as	Irdabisant
Sponsor	Teva Branded Pharmaceutical Products R&D, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CEP-26401 CI brief — competitive landscape report
CEP-26401 updates RSS · CI watch RSS
Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI